Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2003 6
2004 5
2005 6
2006 3
2007 5
2008 6
2009 12
2010 11
2011 6
2012 21
2013 24
2014 18
2015 18
2016 16
2017 16
2018 15
2019 19
2020 20
2021 27
2022 30
2023 29
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Results by year

Filters applied: . Clear all
Page 1
Effects of different exercise intensities or durations on salivary IgA secretion.
Uchino T, Uchida M, Ito R, Fujie S, Iemitsu K, Kojima C, Nakamura M, Shimizu K, Tanimura Y, Shinohara Y, Hashimoto T, Isaka T, Iemitsu M. Uchino T, et al. Among authors: hashimoto t. Eur J Appl Physiol. 2024 Apr 18. doi: 10.1007/s00421-024-05467-6. Online ahead of print. Eur J Appl Physiol. 2024. PMID: 38634902
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: hashimoto t. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: hashimoto t. Target Oncol. 2024 Mar 28. doi: 10.1007/s11523-024-01047-y. Online ahead of print. Target Oncol. 2024. PMID: 38546942
285 results